Heidi raises $340M to scale clinical AI agents

Australian healthcare AI company Heidi announced US$340 million in new funding — a US$100 million Series C led by Blackbird valuing Heidi at US$900 million, plus a US$240 million growth investment from General Catalyst’s Customer Value Fund — to expand from clinical documentation into supervised agentic action, software that takes steps in care with a clinician still in control, across health systems.

HEALTH desk — a major AI scribe scales into paid agentic care workflows with hospital-system distribution, not just another note-taking seed round.

The second check is not the same as the equity round. Alongside it, Heidi says it secured a US$240 million growth investment led by General Catalyst’s Customer Value Fund, which the company shortens to CVF. The company says that check provides large-scale go-to-market capacity. Go-to-market, often shortened to GTM, means the sales and distribution work of getting a product into customers’ hands. The company says the equity round plus that growth investment bring total new funding to US$340 million. Do not read US$340 million as a second valuation. US$900 million is the price on the company. US$340 million is the new money.

A same-day company note at heidihealth.com/en-au/blog/series-c uses a looser sentence: “The new investment values Heidi at $900 million.” That line folds the growth check into the valuation sentence. The news post ties US$900 million to the Series C round. File both wordings. They are not two different prices. The note has no hour stamp.

What the company says the money is for. The news post says the investment deepens adoption inside health systems, brings agentic capabilities to the work around a patient visit, and keeps building the regulatory and clinical safety foundations those capabilities require. Agentic, here, means software that takes steps in a workflow, not only writes a note. Supervised means a clinician still decides. The company says the clinician stays in control of every decision, and that part of the round funds clinical evidence, quality systems, and regulatory submissions. It also says it will keep working with regulators so each product goes through the appropriate pathway. The same post then prints one limit, with no reason attached: “The coming product capabilities will not be available in the UK and EU.” File that sentence as the company’s. Do not invent a ban, a clearance, or a rule name the page does not print.

The scale lines are the company’s, and two pages do not use the same noun for the weekly count. The news post’s subhead says clinicians trust Heidi across 2.8 million patient visits a week in 190 countries. The About box on that post says Heidi supports around 2.8 million patient interactions each week, in 110 languages, from 190 countries. The series-c note says 2.8 million patient visits every week, across 190 countries and 110 languages. A visit and an interaction are not defined as the same thing on these pages. Do not merge the words. Around 2.8 million is the company’s figure either way. This desk did not count the clinics.

Lifetime use, still the company. The news post says that two years after launch, Heidi has supported more than 175 million patient visits, up from 73 million at the Series B, and over 67 million clinical hours, more than tripling since September 2025. The series-c note says “over 175 million visits” and “67 million clinical hours,” without the “more than tripling” line. Annual recurring revenue, shortened to ARR, is the yearly value of current subscriptions if they keep paying. It is not profit. The news post says ARR grew from US$1 million to US$50 million in April 2026, in two years. The series-c note says the same dollar climb and does not print “April 2026.” File April 2026 as the news post’s.

Where it is installed, as the news post names the systems. Since the Series B, the company says enterprise adoption sits at an activation rate of around 62 percent. The page does not define what counts as activated. In the United States, Heidi is used by Beth Israel Lahey Health, which the company calls one of the largest health systems in Massachusetts. In the United Kingdom, Heidi was selected as sole supplier for NHS England Midlands, which the company calls the largest clinical AI procurement in NHS history. A sole supplier means that buyer picked one vendor for that contract. In Australia, the post names the Royal Children’s Hospital Melbourne, Children’s Health Queensland Hospital and Health Service, and Metro South Health. In New Zealand, the post says Heidi was deployed across every emergency department in the country. The series-c note’s shorter list is NHS Midlands, Metro South Health, Health New Zealand, and Beth Israel Lahey Health. It does not repeat the children’s hospitals or the every-emergency-department line. “Largest in NHS history” and “every emergency department” are the news post’s claims. This desk did not audit the contracts.

The product, in the company’s words. An AI scribe writes the clinical note from the visit. Heidi says it has moved past the scribe into a connected platform, with deeper links into major electronic health record systems. An electronic health record, shortened to EHR, is the software a clinic uses to store the chart. Heidi Evidence, which the company describes as context-aware clinical guidelines at the point of care, has answered over 10 million queries since it launched in March 2026. Point of care means during the visit, not in a later research project. The company also says it shipped Remote, its first wearable device, built to capture audio from surgery through community clinics, and Dictate, a voice-to-text feature. The series-c note does not name Evidence, Remote, or Dictate. File those product names as the news post’s.

How the company says the software is built. The news post says Heidi invested early in purpose-built clinical AI rather than relying on frontier models, and that transcription and note generation — the vast majority of its computing — now run almost entirely on technology developed in-house. A frontier model, here, means a general model from a large lab, used as-is. In-house means Heidi says it built the piece itself. The series-c note uses a different phrase: task-specific medical foundation models. A foundation model is a large model trained for a wide job. The note says Heidi built those for medicine’s precision and safety needs. The news post does not use the words “foundation model.” File both sentences as the company’s, on two pages. This desk did not inspect the models, and this filing does not turn the claim into a blueprint.

The ambition, and whose sentence it is. The news post says the world faces a projected shortfall of 11 million health workers by 2030, and that Heidi’s ambition is to double the world’s healthcare capacity while keeping the human connection between clinician and patient. The page does not cite a study for the 11 million. File it as the company’s framing, not a forecast this desk made. Doubling capacity is an ambition. It is not a result.

Named voice on the news post: Dr Thomas Kelly, co-founder and chief executive. He says the ambition was always bigger than writing doctors’ notes, that the shift is from documenting care to helping clinicians act on it, and that the round is about getting an AI Care Partner to every doctor. The Business Wire carry prints “Dr. Thomas Kelly,” with a period. The series-c note says “Dr Tom Kelly.” File the name and the note quote as the company’s. A quote is not a clinical result. Investor lines from Pranav Singhvi at General Catalyst’s CVF, Michael Tolo at Blackbird, and Taylor Brandt at Headline stay in Sources.

The lifetime money line is the About box, not a second announcement. The news post says Heidi was founded in Melbourne, Australia, and has raised US$436.6 million. The figure is printed on this announcement, after the new round, so the company is stating a total that includes it. This desk did not rebuild that total from older rounds. The named investors on that box are Blackbird, General Catalyst, Phoenix Court, Point72 Private Investments, Headline, Possible Ventures, Glitch Capital, and Archangel. The same box says Heidi aligns with NHS requirements, GDPR, HIPAA, and the Australian Privacy Principles, and lists certifications: ISO 27001, SOC 2 Type II, Cyber Essentials Plus, and ISO 42001. GDPR is the European privacy rule. HIPAA is the U.S. health-privacy rule. File the list as the company’s description. It is not a certificate this desk checked, and it is not a reason for the UK and EU product limit above.

What Forbes Australia adds, and only Forbes. Daniel Van Boom’s 22 Sep 2026 story converts the company’s US$900 million into A$1.26 billion and calls that unicorn status, a private company priced at a billion or more in local currency. The headline rounds the new funding to A$470 million and the valuation to A$1.2 billion. Those Australian-dollar figures are Forbes’s conversion and rounding. The company’s figures stay in U.S. dollars. Do not file A$470 million as a different raise. Forbes calls the General Catalyst money customer-acquisition finance, similar to a debt facility: usable for marketing and sales, with revenue from customers won that way paid back to the firm with interest. Kelly, via Forbes, says the US$240 million commitment can last roughly four and a half years, and that it means fewer equity raises every 12 to 18 months. The company page does not use the word debt. Do not upgrade “growth investment” into a loan the company printed. Forbes also says Blackbird called Heidi its fastest-growing investment, and its fastest-growing portfolio company. Kelly, via Forbes, says the lion’s share of spending is in new markets such as France and Germany, that he declined to disclose losses, that the company would likely stay unprofitable on a GAAP basis because of share-based pay, and that it should be cash-flow neutral by the end of next year. GAAP is the standard set of accounting rules. Cash-flow neutral means money in and money out roughly match in a month. Forbes says Blackbird said in August that it owned 35 percent of Heidi, and that the Series C lead was not in that figure. Forbes says Kelly said about half of users stay on free tools and about half pay. File every one of those lines as Forbes’s interview, not as sentences on the company blog. This desk did not see the interview tape.

What Axios adds, from the preview this desk could read. Brock E.W. Turner’s Axios Pro note, dated 22 Sep 2026, headlines “Heidi raises $340M from General Catalyst and Blackbird.” The visible lede calls Heidi an Australian medical scribe and care platform and says it raised $340 million, including $100 million in equity led by Blackbird, valuing the company at $900 million. The big-picture line on that preview — the latest major fundraise for an AI scribe with bigger aspirations — is Axios’s. The rest of the note sat behind the Pro wall. This desk did not read past the preview, and it does not attribute the US$240 million split, the CVF name, or the Forbes interview lines to Axios.

Plain English for the rest of the card: Series C = a later private round, after earlier checks. valuation = the price the equity round puts on the company. US$900 million is that price. US$340 million is the new money, not a second price. CVF = General Catalyst’s Customer Value Fund. GTM = go-to-market, the work of selling and distributing. agentic = software that takes steps in the work, not only the note. supervised = a clinician still decides. scribe = software that writes the clinical note. EHR = the clinic’s chart software. ARR = the yearly value of current subscriptions. It is not profit. US$1 million to US$50 million, with April 2026 on the news post, is the company’s ARR line. visit and interaction = two words the company uses for the weekly 2.8 million. They are not defined as the same count. sole supplier = one vendor picked for that contract. foundation model = a large model trained for a wide job. The series-c note uses that phrase. The news post says in-house technology. GAAP = standard accounting rules. cash-flow neutral = money in and money out roughly match. This filing is the 22 Sep announcement. It is not an audit of the books.

PRIMARY here: Heidi’s 22 Sep 2026 company blog, “Heidi secures US$340M to scale agents across health systems globally,” datelined NEW YORK — Tier A PRIMARY, the company’s own record. The same-day Business Wire syndication at 09:00 AM EDT is the open carry of that text. The series-c note is a same-day company page with a looser valuation sentence. Forbes Australia’s Daniel Van Boom story and the Axios Pro preview are independent same-day wraps, not substitute primaries. The US$100 million Series C, the Blackbird lead, Phoenix Court, Point72 Private Investments, Headline, the US$900 million round valuation, the US$240 million CVF growth investment, the US$340 million total, the UK and EU limit on coming capabilities, the 175 million visits, the 73 million Series B comparison, the 67 million clinical hours, the US$1 million to US$50 million ARR with April 2026, the around-62-percent activation rate, Beth Israel Lahey Health, NHS England Midlands, the Royal Children’s Hospital Melbourne, Children’s Health Queensland, Metro South Health, every New Zealand emergency department, Evidence’s 10 million queries, Remote, Dictate, the in-house transcription line, and the US$436.6 million raised figure are the news post’s. The “new investment values Heidi at $900 million” sentence, the “patient visits every week” wording, Health New Zealand, and the foundation-model phrase are the series-c note’s. The 09:00 AM EDT stamp is the Business Wire carry’s. The A$1.26 billion and A$470 million conversions, the debt-like description of the CVF check, the four-and-a-half-year line, the fastest-growing line, the France and Germany spending, the cash-flow-neutral target, the GAAP line, the August 35 percent stake, and the half-free half-paid split are Forbes’s. The preview lede and the “bigger aspirations” line are Axios’s. NOT claimed: that US$900 million prices the growth check, that A$470 million is a different raise, that the CVF money is a loan the company printed, a reason for the UK and EU limit, an audited ARR, a counted clinic list, a model this desk inspected, a certificate this desk checked, a stock tip, or investment advice. Distinct from the already-filed ambitious-bio-corpus, envisagenics-boehringer, and fda-nams-nonclinical-rule.